mgl-3196

Small moleculeexperimental

Clinical trial activity

12 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Jun 1, 2011 (NCT01367873)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O
Mol. weight
435.23 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

First in class

Sources

Also known as

  • 2-(3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro(1,2,4)triazine-6-carbonitrile
  • mgl-3196
  • mgl-3196
  • mgl-3196
  • mgl-3196
  • mgl-3196
  • via-3196
  • via-3196
  • via-3196

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04671069Phase 1Jul 26, 2019Madrigal Pharmaceuticals
NCT03900429Phase 3Mar 28, 2019Madrigal Pharmaceuticals
NCT04671056Phase 1Nov 9, 2018Madrigal Pharmaceuticals
NCT04643795Phase 1Oct 24, 2018Madrigal Pharmaceuticals
NCT03413124Phase 1Feb 5, 2018Celerion, Madrigal Pharmaceuticals
NCT03220165Phase 1Aug 6, 2017Madrigal Pharmaceuticals, Worldwide Clinical Trials
NCT03038022Phase 2Feb 1, 2017Madrigal Pharmaceuticals
NCT02912260Phase 2Sep 1, 2016Madrigal Pharmaceuticals
NCT02749578Phase 1Apr 1, 2016Celerion, Madrigal Pharmaceuticals
NCT02542969Phase 1Sep 1, 2015Celerion, Madrigal Pharmaceuticals
NCT01519531Phase 1Jan 1, 2012Madrigal Pharmaceuticals
NCT01367873Phase 1Jun 1, 2011Madrigal Pharmaceuticals
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Madrigal PharmaceuticalsFor profit121232011
CelerionFor profit3012015
Worldwide Clinical TrialsFor profit1012017
3 organizations
Page 1 / 1